World Journal of
Pharmaceutical and Life Sciences

NANOPARTICLES DRUG DELIVERY SYSTEM USING LIPOSOMES FOR CANCER TREATMENT

Ajkia Zaman Juthi*, Tasnim Zaman Bithi, Md. Shaiful Islam Babu, Md. Eman Talukder and Muhammad Sharafat Hossen

ABSTRACT

The first closed bilayer phospholipid systems, called liposomes, were described in 1961 and soon were proposed as drug delivery systems. Nanoparticles particles in the size range 1–100 nm are emerging as a class of therapeutics for cancer. Nanoparticles composed of biodegradable polymers show assurance in fulfilling the stringent requirements placed on these delivery systems, such as ability to be transferred into an aerosol, stability against forces generated during aerosolization, biocompatibility, targeting of specific sites or cell populations in the lung, release of the drug in a predetermined manner, and degradation within an acceptable period of time. Their use offers improved pharmacokinetic properties, controlled and sustained release of drugs and, more importantly, lower systemic toxicity. A number of liposomes (lipidic nanoparticles) are on the market, and many more are in the pipeline. Lipidic nanoparticles are the first nano medicine delivery system to make the transition from concept to clinical application, and they are now an established technology platform with considerable clinical acceptance. We can look forward to many more clinical products in the future.

[Full Text Article]   [Download Certificate]